JP2002535334A - 縮合ヘテロ環状化合物及びこれを神経変性疾患の治療に使用する方法 - Google Patents

縮合ヘテロ環状化合物及びこれを神経変性疾患の治療に使用する方法

Info

Publication number
JP2002535334A
JP2002535334A JP2000594813A JP2000594813A JP2002535334A JP 2002535334 A JP2002535334 A JP 2002535334A JP 2000594813 A JP2000594813 A JP 2000594813A JP 2000594813 A JP2000594813 A JP 2000594813A JP 2002535334 A JP2002535334 A JP 2002535334A
Authority
JP
Japan
Prior art keywords
alkyl
group
disease
hydrogen
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000594813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002535334A5 (enExample
Inventor
ペータース・ダン
グレンボルグ・メッテ
メルラー・アルネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of JP2002535334A publication Critical patent/JP2002535334A/ja
Publication of JP2002535334A5 publication Critical patent/JP2002535334A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2000594813A 1999-01-19 2000-01-13 縮合ヘテロ環状化合物及びこれを神経変性疾患の治療に使用する方法 Pending JP2002535334A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK199900061 1999-01-19
DKPA199900061 1999-01-19
PCT/DK2000/000012 WO2000043397A1 (en) 1999-01-19 2000-01-13 Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
JP2002535334A true JP2002535334A (ja) 2002-10-22
JP2002535334A5 JP2002535334A5 (enExample) 2007-02-22

Family

ID=8089290

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000594813A Pending JP2002535334A (ja) 1999-01-19 2000-01-13 縮合ヘテロ環状化合物及びこれを神経変性疾患の治療に使用する方法

Country Status (10)

Country Link
US (1) US6576641B2 (enExample)
EP (1) EP1147113B1 (enExample)
JP (1) JP2002535334A (enExample)
CN (1) CN1147490C (enExample)
AT (1) ATE328887T1 (enExample)
AU (1) AU776276B2 (enExample)
CA (1) CA2353903A1 (enExample)
DE (1) DE60028538T2 (enExample)
NZ (1) NZ512289A (enExample)
WO (1) WO2000043397A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE311386T1 (de) * 2001-09-24 2005-12-15 Bayer Pharmaceuticals Corp Verfahren zur herstellung von 1,5,6,7- tetrahydropyrrolo(3,2-c)derivaten zur behandlung der fettleibigkeit
KR100553398B1 (ko) 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
KR102074089B1 (ko) 2009-12-04 2020-02-05 선오비온 파마슈티컬스 인코포레이티드 다환형 화합물 및 이의 사용 방법
JP7187437B2 (ja) 2016-07-29 2022-12-12 サノビオン ファーマシューティカルズ インク 化合物および組成物ならびにそれらの使用
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
MX390141B (es) 2017-02-16 2025-03-20 Sunovion Pharmaceuticals Inc Metodos para tratar esquizofrenia
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
CN112135827B (zh) 2018-02-16 2024-01-12 赛诺维信制药公司 盐、晶型及其制备方法
KR20210139376A (ko) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물
WO2021211489A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
PE20242113A1 (es) 2021-10-14 2024-10-28 Incyte Corp Compuestos de quinolina como inhibidores de kras

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5441332A (en) * 1977-06-22 1979-04-02 Sentore Deechiyuude Puuru Rand Treating composition of sickle shaped erythrocyte disease
JPS61106577A (ja) * 1984-09-27 1986-05-24 シンセラボ フロ−〔３，２−ｃ〕ピリジン誘導体、その製造法およびそれを含有する医薬組成物
JPH02115185A (ja) * 1988-09-07 1990-04-27 Synthelabo Sa ４，５，６，７―テトラヒドロフロピリジン誘導体の肥満症治療用医薬への応用
JPH03130288A (ja) * 1989-09-22 1991-06-04 Fujisawa Pharmaceut Co Ltd 二環式アミン化合物およびその製造法
WO1997010218A1 (en) * 1995-09-11 1997-03-20 Hoechst Marion Roussel, Inc. Cyclic nitrones and pharmaceutical compositions containing them

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2566775B1 (fr) 1984-06-27 1986-10-31 Synthelabo Derives de tetrahydro-4,5,6,7 furo ou 1h-pyrrolo(2,3-c)pyridine, leur preparation et leur application en therapeutique
FR2652579B1 (fr) * 1989-10-02 1992-01-24 Sanofi Sa Derives d'hydroxy-2 thiophene et furanne condenses avec un cycle azote, sur procede de preparation et leur application en therapeutique.
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
CA2200469A1 (en) * 1994-10-11 1996-04-18 Takeda Chemical Industries, Ltd. Condensed compounds, their production and use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5441332A (en) * 1977-06-22 1979-04-02 Sentore Deechiyuude Puuru Rand Treating composition of sickle shaped erythrocyte disease
JPS61106577A (ja) * 1984-09-27 1986-05-24 シンセラボ フロ−〔３，２−ｃ〕ピリジン誘導体、その製造法およびそれを含有する医薬組成物
JPH02115185A (ja) * 1988-09-07 1990-04-27 Synthelabo Sa ４，５，６，７―テトラヒドロフロピリジン誘導体の肥満症治療用医薬への応用
JPH03130288A (ja) * 1989-09-22 1991-06-04 Fujisawa Pharmaceut Co Ltd 二環式アミン化合物およびその製造法
WO1997010218A1 (en) * 1995-09-11 1997-03-20 Hoechst Marion Roussel, Inc. Cyclic nitrones and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
WO2000043397A1 (en) 2000-07-27
EP1147113A1 (en) 2001-10-24
DE60028538D1 (de) 2006-07-20
ATE328887T1 (de) 2006-06-15
CN1336929A (zh) 2002-02-20
US20020013336A1 (en) 2002-01-31
EP1147113B1 (en) 2006-06-07
AU776276B2 (en) 2004-09-02
NZ512289A (en) 2003-06-30
AU3033300A (en) 2000-08-07
US6576641B2 (en) 2003-06-10
CN1147490C (zh) 2004-04-28
DE60028538T2 (de) 2007-06-21
CA2353903A1 (en) 2000-07-27

Similar Documents

Publication Publication Date Title
US8809534B2 (en) Compounds as tyrosine kinase modulators
IL234743A (en) –7) –3) –5) –n (3– trifluorophenyl) - h3– amidazo [5,4– c] pyridine – 2 – yl– (h1– imidazole – 5 – yl) pyridine – 3 – yl) –3 - Methylbutamide
JP2020506903A (ja) Ｍａｇｌ阻害薬としての複素環式スピロ化合物
CN110256440B (zh) 酞嗪异噁唑烷氧基衍生物、其制备方法、药物组合物和用途
US10548883B2 (en) Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor
JP2002531552A (ja) イオンチャネル調節剤としての新規ベンズイミダゾロン−、ベンズオキサゾロン−又はベンゾチアゾロン−誘導体
JP2012111777A (ja) 薬剤活性のあるスルホニルアミノ酸誘導体
JP2012517971A (ja) キナーゼ阻害薬としての［１，２，４］トリアゾロ［１，５−ａ］ピリジン類
US9340555B2 (en) Compounds as tyrosine kinase modulators
JP2000501432A (ja) 新規インドール―２，３―ジオン―３―オキシム誘導体
WO2021060453A1 (ja) 架橋型光学活性２級アミン誘導体
US11220503B2 (en) Phthalazine derivatives, preparation method, pharmaceutical composition and usage thereof
CA2890685A1 (en) Substituted 1,6-naphthyridines
JP2002535334A (ja) 縮合ヘテロ環状化合物及びこれを神経変性疾患の治療に使用する方法
JP2002531456A (ja) ８−アザビシクロ〔３．２．１〕オクト−２−エン及び−オクタン誘導体
US7595336B2 (en) Isatine derivatives with neurotrophic activity
EP3814334A1 (en) 4-substituted phenyl-1,3,5-triazine derivatives as modulators of trk receptors
EP4229058B1 (en) Substituted 4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)thiophene-2-carboxamide derivatives and use thereof
JP2005506335A (ja) 神経栄養剤としてのｎ−ヘテロシクリルヒドラジド
WO2005053688A1 (en) Substituted furo[2,3-g] indazoles for the treatment of glaucoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061228

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100629

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101214